TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

So far, so good: TAVR comparable to open heart surgery after 5 years in low-risk patients
Michael J. Reardon, MD, shared the highly anticipated data with a large audience at ACC.25 in Chicago. Overall, he said, these five-year findings suggest TAVR with a supra-annular, self-expanding valve is a safe and effective alternative to SAVR.
Cardiologists make case against routine interventions for asymptomatic severe AS
Aortic valve replacement is likely inevitable for patients with asymptomatic severe aortic stenosis. Immediately planning for TAVR or SAVR, however, may not always be the answer.
AHA still working to find more patients with severe aortic stenosis who may require care
The initiative is designed to help identify more patients who may require aortic valve replacement. Brian Lindman, MD, provided an update on the project's efforts.
The biggest names in TAVR are sharing new data at ACC.25
The country’s two biggest TAVR vendors both plan on making a splash at ACC.25. Medtronic and Edwards Lifesciences spoke to Cardiovascular Business about their plans for the three-day event in Chicago.
New drug shows early potential to treat aortic stenosis in some patients without TAVR, SAVR
The drug in question, ataciguat, could help heart patients avoid aortic valve replacement—or at least put it off until later in life.

PCI before TAVR a winning combination for many heart patients

“No clear recommendation currently exists in U.S. or European guidelines for performing PCI in addition to TAVR,” researchers wrote. The group hoped its study could provide some clarity.

The SAPIEN 3 Ultra (S3U) transcatheter heart valve from Edwards Lifesciences is

TAVR outperforms SAVR when treating women, historic all-female trial confirms

The study, presented at ESC Congress 2024 in London, confirmed that TAVR was associated with significantly better outcomes than surgery when treating female patients.

A TAVR procedure being performed at Northwestern Medicine in Chicago. These structural heart procedures require a team approach.

TAVR complication rates keep falling, highlighting considerable progress

Complications are also down after SAVR, researchers noted, though the drop has been much more dramatic for TAVR patients. The new analysis was based on Medicare data from more than 210,000 patients.

AI for TAVR, robot-guided echo and more: Key research at ESC Congress 2024

ESC's annual meeting is always one of the world's largest gatherings of cardiologists and other cardiology professionals. This year's 4-day event will be no different.

Boston Scientific TAVR ACURATE Prime Aortic Valve System

Boston Scientific’s new TAVR valve gains CE mark approval

The self-expanding Acurate Prime Aortic Valve System was designed with improved valve positioning in mind. According to Boston Scientific, it it will be available in more sizes than the company's previous TAVR device to ensure it can treat as many heart patients as possible.

CRF announces late-breaking clinical trials for TCT 2024

The Cardiovascular Research Foundation has announced 10 late-breaking clinical trials and 15 late-breaking clinical science sessions for TCT 2024 in Washington, DC. Topics will include TAVR and other structural heart procedures, artificial intelligence and much more.

TAVR and SAVR linked to comparable long-term outcomes, new meta-analysis confirms

Researchers combined data from three well-known clinical trials—NOTION, Evolut Low Risk and PARTNER 3—and evaluated thousands of low-risk patients who presented with severe aortic stenosis.

TAVR planning with GE Healthcare's Valve Assist 2 technology

TAVR planning with valve-sizing software: GE Healthcare tech easier to use than competition

Planning ahead of TAVR procedures with semi-automated sizing software helps cardiologists match each patient with the best device possible; not undersized or oversized, but something in the middle that would make Goldilocks proud.

Around the web

Radiology Business

The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business

Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

TAVR

So far, so good: TAVR comparable to open heart surgery after 5 years in low-risk patients

Cardiologists make case against routine interventions for asymptomatic severe AS

AHA still working to find more patients with severe aortic stenosis who may require care

The biggest names in TAVR are sharing new data at ACC.25

New drug shows early potential to treat aortic stenosis in some patients without TAVR, SAVR

Around the web